You are here: Welcome to the MPKB » Welcome to the MPKB » Starting the Marshall Protocol » Working with your physician » Helping a concerned physician to become comfortable with the MP
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:starting:physician:reluctant [04.15.2019] – [Specific research] sallieqhome:starting:physician:reluctant [04.15.2019] – [Specific research] sallieq
Line 185: Line 185:
 {{ :home:mp:olmesartan:4hr_6hr_matched.jpg?nolink&300|4 hourly compared to 6 hourly dosing}} {{ :home:mp:olmesartan:4hr_6hr_matched.jpg?nolink&300|4 hourly compared to 6 hourly dosing}}
  
 +The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed>long:16508590}})) 
  
 short extract for each research study follows: short extract for each research study follows:
  
-The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed>long:16508590}})) Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. (({{pubmed>long:24772521}}))+ 
 +Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. (({{pubmed>long:24772521}})) 
 + 
 Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat)(({{pubmed>long:88888888}})) Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat)(({{pubmed>long:88888888}}))
  
-Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed>long:19304450}})) Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity & apoptosis induction against tumour cells in breast cancer (({{pubmed>long:26138656}})) +Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed>long:19304450}}))  
-10) Alzheimer's disease and dementia1 (({{pubmed>long:20068258}}))+ 
 +Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity & apoptosis induction against tumour cells in breast cancer (({{pubmed>long:26138656}})) 
 +10)  
 + 
 +Alzheimer's disease and dementia1 (({{pubmed>long:20068258}})) 
 + 
 prevent migraines (({{pubmed>long:12503978}})) prevent migraines (({{pubmed>long:12503978}}))
 +
 +
 inhibit liver fibrosis and aid liver healing (({{pubmed>long:12871826}})) inhibit liver fibrosis and aid liver healing (({{pubmed>long:12871826}}))
-6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats (({{pubmed>long:23775504}}))+ 
 + 
 +6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats (({{pubmed>long:88888888}} )) 
 + 
 protect the mitochondria from age-associated damage from oxidation (({{pubmed>long:12709417}})) protect the mitochondria from age-associated damage from oxidation (({{pubmed>long:12709417}}))
 +
 +
 reduce liver fibrosis (({{pubmed>long:19303015}})) reduce liver fibrosis (({{pubmed>long:19303015}}))
 +
 +
 treatment of anxiety and stress-related disorders (({{pubmed>long:15837532}})) treatment of anxiety and stress-related disorders (({{pubmed>long:15837532}}))
 +
 +
 inflammation in myocarditis (({{pubmed>long:16336207}})) inflammation in myocarditis (({{pubmed>long:16336207}}))
 +
 +
 C-reactive protein, one of the acute phase proteins that increase during systemic inflammation (({{pubmed>long:16939632}})) C-reactive protein, one of the acute phase proteins that increase during systemic inflammation (({{pubmed>long:16939632}}))
 +
 +
 cytokine damage (({{pubmed>long:88888888}})) cytokine damage (({{pubmed>long:88888888}}))
  
Line 212: Line 237:
  
 * treatment with olmesartan inhibited bone loss (({{pubmed>long:25363367}})) * treatment with olmesartan inhibited bone loss (({{pubmed>long:25363367}}))
 +
 +
 * olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed>long:25904217}})) * olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed>long:25904217}}))
 +
 +
 * decreases viability of malignant cell lines(({{pubmed>long:28666209}})) * decreases viability of malignant cell lines(({{pubmed>long:28666209}}))
 +
 +
 * carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{pubmed>long:19124398}})) * carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{pubmed>long:19124398}}))
 +
 +
 * improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}})) * improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}}))
 +
 +
 * improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed>long:23303198}})) * improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed>long:23303198}}))
 +
 +
 * OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}})) * OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))
 +
 +
 * prevention of microalbuminuria in patients with type 2 diabetes and hypertension (({{pubmed>long:22418908}})) * prevention of microalbuminuria in patients with type 2 diabetes and hypertension (({{pubmed>long:22418908}}))
 +
 +
 Recent studies showed treatment with olmesartan inhibited bone loss (({{pubmed>long:25363367}})),  Recent studies showed treatment with olmesartan inhibited bone loss (({{pubmed>long:25363367}})), 
 +
 +
 olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed>long:25904217}})),  olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed>long:25904217}})), 
 +
 +
 decreases viability of malignant cell lines (({{pubmed>long:28666209}})),  decreases viability of malignant cell lines (({{pubmed>long:28666209}})), 
-carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{pubmed>long:19124398}})),+ 
 + 
 +carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced  
 +the volume of larger atherosclerotic plaques (({{pubmed>long:19124398}})), 
 + 
 improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}})), improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}})),
 +
 +
 improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed>long:23303198}})), improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed>long:23303198}})),
 +
 +
 OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}})) OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))
  
home/starting/physician/reluctant.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.